N

NuvOx Therapeutics, Inc.

NUOXFiled

NuvOx Therapeutics, Inc. · NYSE American · latest filing 2026-09-16

Report source
One-minute decisionBASIC RESEARCHSource completeness · 68%

NuvOx proposes a $6–$8 IPO to fund clinical development, but completion and listing remain unconfirmed.

As of the September 16, 2026 S-1/A, NuvOx proposed a 2.86 million-share IPO at $6–$8 per share, subject to effectiveness and NYSE American approval.

Where does the money go?Awaiting verificationS-1/A · 2026-09-16
Ownership and votingAwaiting verified holder data— economic · — voting
Next disclosed checkpointNo verified closing or trading date is supplied; effectiveness and final NYSE American approval remain conditions.S-1/A · 2026-09-16

Capital destination

Awaiting verification

S-1/A · 2026-09-16

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · S-1/A ↗
Next checkNo verified closing or trading date is supplied; effectiveness and final NYSE American approval remain conditions.
Latest filing2026-09-16

Capital destination

Awaiting verification

S-1/A · 2026-09-16

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · S-1/A ↗
BOOKRUNNERS / LEAD UNDERWRITERSBookrunners / lead underwriters
NOT YET DISCLOSED

Names not yet published

Fully diluted valuation bridge

StatusReference
Awaiting verificationSource ↗

Basic-price scenario

A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.

Check the source · S-1/A ↗

Holder data awaits verification

Ownership percentages are supplied on an economic beneficial-ownership basis; voting interests are not separately disclosed in the excerpt. · 2026-09-16

Ownership percentages are supplied on an economic beneficial-ownership basis; voting interests are not separately disclosed in the excerpt.

One disclosed holder; not a complete ownership distribution.Check the source · S-1/A ↗

Conditional lock-up timeline

StatusReference
Awaiting verificationSource ↗

Financial quality and runway

StatusReference
Awaiting verificationSource ↗

Latest filing update

Loading saved filing update…

SEC filing history

Loading filing history…

Risk 1

NanO2 requires additional clinical testing and may not generate data sufficient for regulatory approval.

Potential impact
Awaiting verification
Monitor
No verified closing or trading date is supplied; effectiveness and final NYSE American approval remain conditions.
SEC EDGAR

S-1/A

2026-09-16

Open SEC filing ↗